Metformin administration improves endothelial function in women with polycystic ovary syndrome

被引:133
作者
Diamanti-Kandarakis, E
Alexandraki, K
Protogerou, A
Piperi, C
Papamichael, C
Aessopos, A
Lekakis, J
Mavrikakis, M
机构
[1] Univ Athens, Sch Med, Laiko Gen Hosp, Endocrine Sect,Dept Med 1, Athens 14578, Greece
[2] Univ Athens, Alexandra Univ Hosp, Sch Med, Vasc Lab,Dept Clin Therapeut, Athens, Greece
[3] Univ Athens, Sch Med, Biol Chem Lab, GR-11527 Athens, Greece
关键词
D O I
10.1530/eje.1.01910
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters. Design: Descriptive clinical trial. Methods: Forty young women, 20 with PCOS and 20 normal women of similar age and body mass index were studied. Metformin (1700 mg daily) was administered for 6 months to the PCOS group. The endothelium status and the metabolic and hormonal profile were studied in both groups, as well as after metformin, by flow-mediated dilatation (FMD) on the brachial artery and by measurements of plasma endothelin-1 (ET-1) levels. Results: FMD was impaired in the PCOS group when compared with controls (3.24 +/- 0.71%, vs 8.81 +/- 1.07% respectively, P < 0.0001), but this difference normalized after metformin treatment (PCOSpost-metformin vs controls: 8.17 +/- 1.26 vs 8.81 +/- 1.07%, P = 0.70) since the values significantly improved after metformin treatment (PCOSpre-metformin VS PCOSpost-metformin: 3.24 +/- 0.71 vs 8.17 +/- 1.26%, P = 0.003). ET-1 levels were significantly higher in the PCOS women compared with the control group (7.23 +/- 0.50 vs 4.99 +/- 0.69 fmol/l, P = 0.01), they improved significantly after metformin treatment (PCOSpre-metformin vs PCOSpost-metformin: 7.23 +/- 0.50 vs 3.57 +/- 0.60 fmol/l, P < 0.0001) and their difference compared with the control group was reversed (PCOSpost-metformin vs controls: 3.57 +/- 0.60 vs 4.99 +/- 0.69fmol/l, P = 0.13). Metformin administration improved hyperandrogenemia. However, in this study, mathematical methods used to assess insulin resistance failed to show any detected alteration after treatment with metformin. Conclusions: PCOS women were found to exhibit endothelial dysfunction compared with controls, which was reversed 6 months after metformin administration.
引用
收藏
页码:749 / 756
页数:8
相关论文
共 50 条
[1]   Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization [J].
Birdsall, MA ;
Farquhar, CM ;
White, HD .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (01) :32-35
[2]   Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes [J].
Caballero, AE ;
Arora, S ;
Saouaf, R ;
Lim, SC ;
Smakowski, P ;
Park, JY ;
King, GL ;
LoGerfo, FW ;
Horton, ES ;
Veves, A .
DIABETES, 1999, 48 (09) :1856-1862
[3]   NONINVASIVE DETECTION OF ENDOTHELIAL DYSFUNCTION IN CHILDREN AND ADULTS AT RISK OF ATHEROSCLEROSIS [J].
CELERMAJER, DS ;
SORENSEN, KE ;
GOOCH, VM ;
SPIEGELHALTER, DJ ;
MILLER, OI ;
SULLIVAN, ID ;
LLOYD, JK ;
DEANFIELD, JE .
LANCET, 1992, 340 (8828) :1111-1115
[4]   Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome [J].
Christian, RC ;
Dumesic, DA ;
Behrenbeck, T ;
Oberg, AL ;
Sheedy, PF ;
Fitzpatrick, LA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) :2562-2568
[5]   Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force [J].
Corretti, MC ;
Anderson, TJ ;
Benjamin, EJ ;
Celermajer, D ;
Charbonneau, F ;
Creager, MA ;
Deanfield, J ;
Drexler, H ;
Gerhard-Herman, M ;
Herrington, D ;
Vallance, P ;
Vita, J ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :257-265
[6]   Insulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscle [J].
Cusi, K ;
Maezono, K ;
Osman, A ;
Pendergrass, M ;
Patti, ME ;
Pratipanawatr, T ;
DeFronzo, RA ;
Kahn, CR ;
Mandarino, LJ .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (03) :311-320
[7]   POLYCYSTIC-OVARY-SYNDROME AND RISK FOR MYOCARDIAL-INFARCTION - EVALUATED FROM A RISK FACTOR MODEL BASED ON A PROSPECTIVE POPULATION STUDY OF WOMEN [J].
DAHLGREN, E ;
JANSON, PO ;
JOHANSSON, S ;
LAPIDUS, L ;
ODEN, A .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1992, 71 (08) :599-604
[8]   The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome [J].
Diamanti-Kandarakis, E ;
Mitrakou, A ;
Raptis, S ;
Tolis, G ;
Duleba, AJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (08) :2699-2705
[9]   Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome [J].
Diamanti-Kandarakis, E ;
Kouli, C ;
Alexandraki, K ;
Spina, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (03) :1273-1276
[10]   Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome [J].
Diamanti-Kandarakis, E ;
Kouli, C ;
Tsianateli, T ;
Bergiele, A .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 138 (03) :269-274